Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Summary

Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed with open label 2.0mg ranibizumab.

Timeline

Start

2010-11

Primary completion

2012-12

Completion

2013-02

Drugs

Indications